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Summary We have reported previously that the anti-emetic efficacy of single agent 5HT3 antagonists is not maintained when analysed with
the measurement of cumulative probabilities. Presently, the most effective anti-emetic regimen is a combination of a 5HT3 antagonist plus
dexamethasone. We, therefore, assessed the sustainment of efficacy of such a combination in 125 patients, scheduled to receive cisplatin
2 70 mg m-2 either alone or in combination with other cytotoxic drugs. Anti-emetic therapy was initiated with 10 mg of dexamethasone and 3
mg of granisetron intravenously, before cisplatin. On days 1-6, patients received 8 mg of dexamethasone and 1 mg of granisetron twice daily
by oral administration. Protection was assessed during all cycles and calculated based on cumulative probability analyses using the method
of Kaplan-Meier and a model for transitional probabilities. Irrespective of the type of analysis used, the anti-emetic efficacy of
granisetron/dexamethasone decreased over cycles. The initial complete acute emesis protection rate of 66% decreased to 30% according to
the method of Kaplan-Meier and to 39% using the model for transitional probabilities. For delayed emesis, the initial complete protection rate
of 52% decreased to 21% (Kaplan-Meier) and to 43% (transitional probabilities). In addition, we observed that protection failure in the
delayed emesis period adversely influenced the acute emesis protection in the next cycle. We conclude thatthe anti-emetic efficacy of a 5HT3
antagonist plus dexamethasone is not maintained over multiple cycles of highly emetogenic chemotherapy, and that the acute emesis
protection is adversely influenced by protection failure in the delayed emesis phase.
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Nausea and vomiting are the most distressing aspects of cancer
chemotherapy (Coates et al, 1983). The prevention and treatment
ofthese symptoms was greatly improved with the development of
selective 5HT3-receptor antagonists, which control nausea and
vomiting in more than 70% ofcisplatin-treated patients in the first
cycle of chemotherapy (Marty et al, 1990; de Mulder et al, 1990;
Hainsworth et al, 1991). Anti-emetic protection against both acute
and delayed emesis is improved further by the combined use of a
5HT3 antagonist plus dexamethasone (Roila et al, 1991; Smith et
al, 1991; Ahn et al, 1994; Hesketh et al, 1994; Italian Group for
Antiemetic Research, 1995).
We have shown recently by measuring cumulative probabilities
that the anti-emetic efficacy of single agent 5HT3 antagonists over
multiple cycles of cisplatin chemotherapy is not maintained (de
Wit et al, 1996). With the 5-day use of the 5HT3 antagonist
tropisetron over six cycles of weekly high-dose cisplatin, the
initial complete protection rate of 71% during the first 24h
decreased to 43% in the sixth cycle. Likewise, the complete
protection rate of31% during days 2-5 decreased to 6%.
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As the combination ofa 5HT3 antagonist plus dexamethasone is
now the gold standard anti-emetic regimen in highly emetogenic
chemotherapy, we investigated whether the efficacy ofthis combi-
nation is maintained during cisplatin chemotherapy administered
every 2-3 weeks.
METHODS
Patients
Eligibility criteria required the following: highly emetogenic
chemotherapy for the first time, with a dose of cisplatin
2 70 mg m-2, either alone or in combination with other cytotoxic
drugs, in patients of 16 years and older, with a WHO performance
score < 2. Patients wererequired toreceive all chemotherapy as in-
patients. The protocol excluded patients with a current or recent
illness that could confound the study, those who wereexperiencing
nausea and vomiting of an organic aetiology, had acute nausea or
vomiting within 7 days prestudy, had received any anti-emetic
medications, corticosteroids, narcotics (unless chronically admin-
istered) or benzodiazepines (except small doses given as sleeping
medication) within 7 days prestudy. As required for the
chemotherapy, each patient had a leucocyte count 2 3000 mm-3,
platelet count 2 100 000 mm-3, serum creatinine < 120 jmol 1-' or
creatinine clearance . 60 ml min-' and bilirubin < 25 Jmol 1-'.
Written informed consent was obtained from all patients, and
the study was conducted according to the guidelines ofthe institu-
tional review boards.
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Chemotherapy
Cisplatin was administered over 3 h, preceded by 1000 ml of
dextrose-saline over 4 h and followed by 2000 ml of dextrose-
saline over 8 h. Other cytotoxic drugs were allowed on day 0;
these drugs were to be given after the administration of cisplatin.
Patients received up to six consecutive cycles with an interval of2
or 3 weeks.
Anti-emetic therapy on day 0
Dexamethasone (10 mg) in 50 ml of 0.9% saline was infused
over 15 min to complete 20 min before the start of cisplatin.
Granisetron (3 mg) in 10 ml of0.9% saline was infused over 30 s
to complete 5 min before the start ofcisplatin. Granisetron rescue
doses of3 mg were prepared and administered in the same way as
for the initial prophylactic dose of granisetron. Two rescue doses
were allowed only during the first 24 h after the start of
chemotherapy (day 0).
Anti-emetic therapy on days 1-6
Patients received 8 mg of dexamethasone orally twice a day and
3 mg of granisetron orally twice a day from day 1 to day 6. All
tablets were blister packed, and the appropriate quantity was
packed in a carton.
Efficacy assessments
On day 0 (first 24 h after the start of cisplatin, acute emesis), 6-
hourly assessments of the severity of nausea and the number of
retches and vomits were made by trained staffnurses. Nausea was
graded as follows: mild, able to eat, reasonable intake; moderate,
intake significantly decreased, but can eat; severe, no substantial
intake. On days 1-6 (delayed emesis), these assessments were
noted on adiary card on adaily basis by the patient. The following
definitions were used: complete protection (CP), no vomiting and
no or mild nausea; major protection (MP), 1-2 vomits, and/or
moderate nausea; failure (F), 2 3 vomits, and/or severe nausea;
non-complete protection, the sum ofMP and F.
Statistical analysis
The anti-emetic efficacy was calculated using two different models.
Cumulativeprobabilities ofcompleteprotection
CP = P (CPcyclei + IICPcyclei) X P (CPcyclei)
over multiple cycles were calculated using the method of Kaplan
and Meier (1958), where non-complete protection was the end
point. The calculations were derived from product and addition
rules for probabilities, and Bayes theorem (Ingelfinger et al, 1983,
pp. 10-16). By applying this two-state model, the probability was
tested to achieve CP during every cycle ofchemotherapy.
A three-state model forcumulative transitionalprobabilities
CP = P (CPcyclei + IICP(cyclei)X P (CPcyclei)
+ P (CPcycle i+IIMPcyclei) x P(MPcyclei)
was used (CP, MP, F), based on the Markov concept for transi-
tional probabilities and with F as the end point (Beck and Panker,
1983; de Wit et al, 1996). This analysis investigated the proba-
bility of achieving CP in a given cycle of chemotherapy when
having been in the state CP or MP during previous cycles.
A withdrawal was defined as a patient who actually stopped the
anti-emetic study medication during the conduct ofthe study. The
term 'protocol violation' was used for a patient who violated the
protocol without recognition during the conduct of the study and
therefore continued the study at the moment of violation.
Withdrawals and protocol violations unrelated to anti-emetic study
medication, e.g. discontinuation because of tumour progression,
decline in performance status, toxicity other than nausea and
vomiting, a decrease in the dose ofcisplatin to below 50 mg m-2 at
any time during the course oftreatment, the firstprescription or an
increase in the dosages of narcotic analgesics or benzodiazepines
and incomplete follow-up, were censored.
Withdrawals and protocol violations related to the study
medication were considered as failures. Acute and delayed emesis
were analysed separately. Ifapatient withdrew for a study medica-
tion-related reason after day 6 of a cycle and before day 0 of the
next cycle, the patient was regarded as a failure in the next cycle
for both the acute and the delayed emesis phase. Patients with
acute emesis failure were not eligible for further protocol treat-
ment and were taken offthe study.
Cumulative probabilities of CP were used in the log rank test
based on variances for testing according to sex and age. All
P-values refer to two-tailed significance testing. Confidence
intervals of cumulative probabilities of CP were calculated
with Greenwood's formula (Kalbfleisch and Prentice, 1980).
Table 1 Number of entered and withdrawn patients
Reason for withdrawal Day 0 Days 1-6 After days 0-6
Withdrawal related to exposition anti-emetic study medication
Lack of anti-emetic protection 3 16 2
Possible related adverse experiences 1 1 1
Withdrawal unrelated to exposition anti-emetic study medication
Chemotherapy-related side-effects 1 10
Refusal further chemotherapy not caused by lack of anti-emetic protection 2 2
Mistakes in execution of protocol 1 1 1
Completed chemotherapy regimen 14
Tumour progression/other therapy 21
Total withdrawals 5 21 51
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Table 2 Protocol violators
Protocol violation criteria Day 0 Days 1-6
Protocol violation related to exposition anti-emetic study medication
Additional anti-emetics used 3 3
Protocol violation unrelated to exposition anti-emetic study medication
Decrease in the dose of cisplatin to < 50 mg m-2 3
Dose cisplatin > 15% increase in the dose in cycle 1 3
Compliance < 80% by oral medication and worse than complete protection 7
Additional i.v. granisetron > 25 h after start of cisplatin 2
Total violations 9 12
Table 3 Number of recorded response states and evaluable patients
Acute emesis phase: recorded states and number of evaluable patients
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
Ndyo= 125 Nday0 = 98 Nday O=81 Nday 0= 62 NdYO= 54 Nday o= 48
Completeprotection&yO 79 66% 58 64% 45 63% 32 55% 23 50% 20 44%
Majorprotectionlay0 22 18% 23 25% 15 21% 17 29% 11 24% 15 33%
Failureday0 1916% 10 11% 1217% 916% 12 26% 10 22%
Evaluable patients 120 100% 91100% 72 100% 58 100% 58 100 45 100%
Delayed emesis phase: recorded protection states and number of evaluable patients
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6
Ndy,,= 124 Nday1-6 =97 Nday1.= 78 Nday1-. = 62 Nd,,1 =54 Nday 1- =48
Complete protectiondays16 55 47% 58 62% 45 60% 32 57% 24 48% 18 40%
Majorprotectionay,s1-6 32 27% 20 22% 16 21% 12 21% 11 22% 12 27%
Failuredays14 30 26% 1516% 1419% 12 21% 15 30% 15 33%
Evaluable patients 117 100% 93 100% 75 100% 56 100% 50 100% 45 100%
N, number of entered patients; CP, complete protection; MP, major protection; F, failure.
Confidence intervals (CI) of one proportion were constructed for
cumulative transitional probabilities ofCP.
Missing data as a result of sleeping during a 6-h assessment
period on day 0 were presumed to represent no nausea and
vomiting. The emetic response for days 1-4 was calculated ifday
5 and/or 6 was missing.
One unit of alcohol was defined as 50 ml of spirits, 150 ml of
wine or 300 ml ofbeer.
RESULTS
From January 1993 to May 1995, 125 patients (43 male, 82
female; mean age 56 years, s.d. 12 years, range 16-82 years) were
enrolled in the study. Some 76% ofpatients had fewer than 2 units
ofalcohol perweek, 16% hadbetween 2 and 10 units perweek and
6% used alcohol more regularly (> 10 units per week).
Predominant primary tumour sites were ovary, non-small-cell
lung cancer and head and neck cancer. The majority of patients
received cisplatin and cyclophosphamide at 3-weekly intervals.
Other frequent combinations were cisplatin and doxorubicin with
or without cyclophosphamide, and cisplatin plus etoposide. Seven
patients received cisplatin and ifosfamide at 2-weekly intervals.
Table 1 shows the numbers of entered and withdrawn patients
per cycle. A total of 62% of the 125 entered patients withdrew
before cycle 6. The majority ofthese patients withdrew forreasons
P(CP)
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
n= 119
n=79
n=62
n=34
n=41
n=33 n=23
- 1 --
n= 20
%,0 1 2 3 4 5 6 7
Cycle (day 0)
Figure 1 Acute emesis protection over consecutive cycles. Bars represent
95% confidence intervals. (-) Cumulative probability of CP
(Kaplan-Meier); (--- -) cumulative transitional probability of CP
not related to the study medication, such as completion of the
chemotherapy regimen or tumour progression. It can be seen from
Table 2 that 21 patients violated the protocol.
n=59
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achieve CP on days 1-6 in cycle 2. Overall protection (sum of
CP + MP) against delayed emesis decreased from 82% to 57% in
the finalcycle (transitional probabilities).
In order to determine whether protection failure during the
delayed emesis period adversely influenced the sustainment of
acute emesisprotection in the subsequent cycles ofchemotherapy,
we investigated the CP rates on day 0 in cycle 2 relative to the
protection that was obtainedduringdays 1-6 incycle 1. In view of
the small numbers remaining on study, we could not perform
analyses in the second and next cycles. It was found that, in
patients who had CP on day 0 ofcycle 1, CP on day 0 ofcycle 2
was less frequently sustained ifthey had failed during days 1-6 of
the first cycle; the relative risk of CPc vs Fcycle dys 1-6=
1.94; 95% CI 1.02-3.69.
5 6 7
Figure 2 Delayed emesis protection over consecutive cycles. Bars
represent 95% confidence intervals. (-) Cumulative probability of CP
(Kaplan-Meier); (---) cumulative transitional probability of CP
Table 3 gives the numbers of recorded response states and
evaluable patients per cycle. Owing to missing data, 120 of the
125 entered patients were evaluable for the acute emesis protec-
tion. Anothertwo with missing dataand onewithdrawalduring the
acute emesis phase ofcycle 1 resulted in 117 evaluable patients for
the delayed emesis protection analysis. The number of evaluable
patients gradually decreased to 45 in cycle 6, mainly as a result of
withdrawal and, in a few cases, owing to missing data. Evaluable
patients were submitted to the core analysis with correction for
withdrawal and protocol violation as described in the Methods
section.
Figure 1 shows the acute emesis protection over the six consec-
utive cycles ofchemotherapy using Kaplan-Meier and the model
for transitional probabilities. Irrespective of the type of analysis
used, the anti-emetic efficacy ofgranisetron/dexamethasone in the
acute emesis phase decreased over cycles. Initial cumulative
(Kaplan-Meier) and cumulative transitional probability CP rates
of66% (95% CI 57-75%) decreased to 30% and to 39% (95% CI
19-59%) in the sixth cycle respectively. Noconfidence interval for
the percentage of 30% could be calculated with Greenwood's
formula as, in cycle 6, no non-CP was observed, causing value 0of
Greenwood's s.e. In the cumulative transitional probability
analysis, patients with MP are kept in the model. The higher
protection rates in the cumulative transitional probability model
thus illustrates the possibility that patients switch from the MP
state to the CP state in consecutive cycles.
Figure 2 shows the curves for the delayed emesis protection. A
similar pattern of decreased efficacy over repeated cycles of
chemotherapy was observed. Initial cumulative (Kaplan-Meier)
and cumulative transitional probability CP rates of 52% (95% CI
42-62%) decreased to 21% (95% CI 13-29%) and to 43% (95%
CI 21-65%) in the sixth cycle respectively. Also, for delayed
emesis protection, the possibility of patients switching from the
MP state to the CP state over cycles was observed. The initial
increase for transitional probability of CP is an artifact caused by
the applied method of calculation: in the Markov method, the
probability for the first cycle is one product, whereas it is the sum
oftwo products for subsequent cycles and, hence, there was a rela-
tive high number of patients with MP on days 1-6 in cycle 1 to
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DISCUSSION
We have reported recently that the anti-emetic efficacy of SHT3
antagonists is not maintained over multiple cycles of cisplatin
chemotherapy (de Wit et al, 1996). In that study, chemotherapy
consisted of an accelerated schedule of 70-80 mg m-2 cisplatin
weekly, and no dexamethasone was added to the anti-emetic
regimen. In the present study, we investigated the protection over
multiple cycles of cisplatin-based chemotherapy in a more
conventional schedule of administration at 2- to 3-weekly inter-
vals, which might lead to fewer cumulative toxic effects. The
currently most effective anti-emetic regimen of a SHT3 antagonist
plus dexamethasone was used. Our second aim was to define the
most suitable cumulative probability analysis, by directly
comparing the method of Kaplan-Meier with a model for transi-
tional probabilities.
It was found that, despite the less intensive chemotherapy
schedule than in ourprevious study and the use ofthe combination
ofthe SHT3 antagonist granisetron plus dexamethasone, acute and
delayed emesis protection were not maintainedduring consecutive
cycles. Irrespective of the type of cumulative probability analysis
used, the initial CP rate against acute emesis of 66% decreased to
30-39% in the sixth cycle. The initial complete delayed emesis
protection rate of52% decreased to 21-43%.
The difference in the decrease in the protection over repetitive
cycles between the two cumulative probability analyses is related
to the keeping of patients with MP in the model for transitional
probabilities. A patient who has one or two vomits during agiven
cycle may regain CP in the nextcycle. The transitionalprobability
analysis allows such patients to remain in the model, as F is the
endpoint. In the Kaplan-Meier method, non-CP at any time is the
end point. In order to achieve CP in the final cycle in the
Kaplan-Meier model, apatient is thus required to have CPduring
all previous cycles. Because CP in the final cycle is the clinically
relevant end result, irrespective of an occasional brief episode of
nausea or one or two vomits in previous cycles, the transitional
cumulative probability analysis is the most suitable method.
An important new observation is our finding that protection
failure in the delayed emesis phase adversely influenced anti-
emetic protection against acute emesis in the next cycle. As
delayed emesis is clearly less well controlled with the current anti-
emetic therapy, this may explain why the initially highly effective
SHT3 antagonists do not sustain theireffectiveness in patients with
delayed symptoms. Our finding ofdecreased anti-emetic efficacy
overrepeated cycles may thus beexplained.
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In summary, we conclude that, irrespective ofthe type ofcumu-
lative probability analysis used, the anti-emetic efficacy of the
combination of the 5HT3 antagonist granisetron plus dexametha-
sone against both acute and delayed emesis is not maintained over
multiple cycles ofhighly emetogenic chemotherapy. In view ofthe
possibility ofpatients regaining CP after occasional briefepisodes
of nausea or vomiting in previous cycles, the cumulative transi-
tional probability analysis is the most suitable method ofanalysing
the sustainment of efficacy over repeated cycles. Finally, unsuc-
cessful protection in the delayed emesis phase adversely influ-
ences acute emesis protection over subsequent cycles, which may
explain the decreased effectiveness of the initially highly
successful 5HT3 antagonists over repeated cycles.
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